Madrigal制药公司:Ervogastat/Resmetirom药物相互作用研究按计划将于2026年第四季度启动

美股速递
May 06

Madrigal Pharmaceuticals, Inc.宣布,其针对Ervogastat/Resmetirom的药物相互作用研究正稳步推进,预计将于2026年第四季度正式启动。这项研究旨在评估该联合疗法在临床应用中可能产生的相互作用,为后续开发提供关键数据支持。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10